Efficacy of alirocumab in heterozygous familial hypercholesterolemia or high cv risk populations: pooled analyses of eight phase 3 trials. Issue 1 (July 2015) - Farnier, M.; Gaudet, D.; Valcheva, V.; Minini, P.; Miller, K.; Cariou, B.